Morepen Laboratories Intrinsic Value
MOREPENLAB • Healthcare
Current Stock Price
₹37.81
Primary Intrinsic Value
₹66.00
Market Cap
₹415.9 Cr
+100.0%
Upside
Median Value
₹75.62
Value Range
₹19 - ₹95
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
MOREPENLAB Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹66.00 | ₹52.80 - ₹79.20 | +74.6% | EPS: ₹3.00, Sector P/E: 22x |
| Book Value Method | asset | ₹94.53 | ₹85.08 - ₹103.98 | +150.0% | Book Value/Share: ₹107.91, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹75.62 | ₹68.06 - ₹83.18 | +100.0% | Revenue/Share: ₹160.73, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹75.62 | ₹68.06 - ₹83.18 | +100.0% | EBITDA: ₹244.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹27.01 | ₹21.61 - ₹32.41 | -28.6% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹19.20 | ₹17.28 - ₹21.12 | -49.2% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹46.35 | ₹41.72 - ₹50.99 | +22.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹75.62 | ₹68.06 - ₹83.18 | +100.0% | ROE: 13.8%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹85.35 | ₹76.81 - ₹93.89 | +125.7% | EPS: ₹3.00, BVPS: ₹107.91 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
MOREPENLAB Intrinsic Value Analysis
What is the intrinsic value of MOREPENLAB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Morepen Laboratories (MOREPENLAB) is ₹75.62 (median value). With the current market price of ₹37.81, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹19.20 to ₹94.53, indicating ₹19.20 - ₹94.53.
Is MOREPENLAB undervalued or overvalued?
Based on our multi-method analysis, Morepen Laboratories (MOREPENLAB) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.74 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.8% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.99x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Morepen Laboratories
Additional stock information and data for MOREPENLAB
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹32 Cr | ₹-129 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹73 Cr | ₹32 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹-91 Cr | ₹-115 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-60 Cr | ₹-76 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹51 Cr | ₹16 Cr | Positive Free Cash Flow | 7/10 |